FOXP3 and type 1 diabetes mellitus: The therapeutic potential of Foxp3+ Tregs has been demonstrated in various preclinical models such as graft-versus-host disease (GVHD) (68), type 1 diabetes mellitus (T1D) (69), systemic lupus erythematosus (70), inflammatory bowel disease (71) and multiple sclerosis (72).